Successful treatment of Erdheim-Chester disease with combination of interleukin-1-targeting drugs and high-dose glucocorticoids

Internal Medicine Journal

Volumn 44, Issue 1, 2014, Pages 90-92

  Darstein, F ^a   Kirschey, S ^a   Heckl, S ^a   Rahman, F ^a   Schwarting, A ^a,b   Schuchmann, M ^c   Galle, P R ^a   Zimmermann, T ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Rheumazentrum   (Germany)

^c KLINIKUM KONSTANZ   (Germany)

Author keywords

Anakinra; Erdheim Chester disease; Histiocytosis; Interleukin 1 receptor antagonist; Treatment

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; COTRIMOXAZOLE; FIBRINOGEN; INTERLEUKIN 2 RECEPTOR; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ANAMNESIS; ANTIBIOTIC THERAPY; APHASIA; ARM WEAKNESS; ARTICLE; BABINSKI REFLEX; BASAL GANGLION; BIOPSY; CASE REPORT; CENTRAL NERVOUS SYSTEM; CEREBELLUM DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES INSIPIDUS; DIZZINESS; DRUG DOSE REDUCTION; DRUG MEGADOSE; ERDHEIM CHESTER DISEASE; ESCHERICHIA COLI; EXOPHTHALMOS; HEADACHE; HEMIPARESIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYDRONEPHROSIS; HYPOPHYSIS; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY FAILURE; LEUKOCYTE; LONG BONE; MALE; MIDDLE AGED; NAUSEA; OUTPATIENT; PARAPLEGIA; PNEUMOCYSTIS PNEUMONIA; POOR GENERAL CONDITION; PRIORITY JOURNAL; RETROPERITONEAL FIBROSIS; RETROPERITONEAL TUMOR; SINUS TACHYCARDIA; URINARY TRACT OBSTRUCTION; UROSEPSIS; VOMITING;

ANAKINRA; ERDHEIM-CHESTER DISEASE; HISTIOCYTOSIS; INTERLEUKIN-1 RECEPTOR ANTAGONIST; TREATMENT;

ACUTE KIDNEY INJURY; DELAYED DIAGNOSIS; DIABETES INSIPIDUS; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; ERDHEIM-CHESTER DISEASE; HUMANS; HYDRONEPHROSIS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MALE; MIDDLE AGED; PARAPARESIS; PREDNISOLONE; RETROPERITONEAL FIBROSIS;

EID: 84892865158     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12329     Document Type: Article

References (18)

1. Chester W. Uber lipoidgranulomatose. Virchows Arch A Pathol Anat Histol 1930; 279: 561-602.
2. Purgina B, Jaffe R, Monaco SE, Khalbuss WE, Beasley HS, Dunn JA etal. Cytomorphology of Erdheim-Chester disease presenting as a retroperitoneal soft tissue lesion. Cytojournal 2011; 8: 22.
3. Arnaud L, Gorochov G, Charlotte F, Lvovschi V, Parizot C, Larsen M etal. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood 2011; 117: 2783-2790.
4. Dion E, Graef C, Haroche J, Renard-Penna R, Cluzel P, Wechsler B etal. Imaging of thoracoabdominal involvement in Erdheim-Chester disease. Am J Radiol 2004; 183: 1253-1260.
5. Pan A, Doyle T, Schlup M, Lubcke R, Schultz M. Unusual manifestation of Erdheim-Chester disease. BMC Gastroenterol 2011; 11: 77.
6. Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol 2012; 24: 53-59.
7. Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, Wechsler J, Brun B, Remy M etal. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine 1996; 75: 157-169.
8. Arnaud L, Hervier B, Néel A, Hamidou MA, Kahn JE, Wechsler B etal. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011; 117: 2778-2782.
9. Miller RC, Villà S, Kamer S, Pasquier D, Poortmans P, Micke O etal. Palliative treatment of Erdheim-Chester disease with radiotherapy: a Rare Cancer Network study. Radiother Oncol 2006; 80: 323-326.
10. Haroche J, Amoura Z, Charlotte F, Salvatierra J, Wechsler B, Graux C etal. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 2008; 111: 5413-5415.
11. Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol 2010; 28: e633-636.
12. Jeon IS, Lee SS, Lee MK. Chemotherapy and interferon-alpha treatment of Erdheim-Chester disease. Pediatr Blood Cancer 2010; 55: 745-747.
13. Myra C, Sloper L, Tighe PJ, McIntosh RS, Stevens SE, Gregson RH etal. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophtalmol 2004; 88: 844-847.
14. Bourke SC, Nicholson AG, Gibson GJ. Erdheim-Chester disease: pulmonary infiltration responding to cyclophosphamide and prednisolone. Thorax 2003; 58: 1004-1005.
15. Aouba A, Georgin-Lavialle S, Pagnoux C, Martin Silva N, Renand A, Galateau-Salle F etal. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010; 116: 4070-4076.
16. Adam Z, Szturz P, Bučková P, Cervinková I, Koukalová R, Rehák Z etal. [Interleukin-1 receptor blockade with anakinra provided cessation of fatigue, reduction in inflammation markers and regression of retroperitoneal fibrosis in a patient with Erdheim-Chester disease - case study and a review of literature]. Vnitr Lek 2012; 58: 313-318.
17. Tran TA, Pariente D, Lecron JC, Delwail A, Taoufik Y, Meinzer U. Treatment of pediatric Erdheim-Chester disease withinterleukin-1-targeting drugs. Arthritis Rheum 2011; 63: 4031-4032.
18. Aubert O, Aouba A, Deshayes S, Georgin-Lavialle S, Rieu P, Hermine O. Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra. Joint Bone Spine 2013; 80: 206-207.